Streetbeat News

Analyst Ratings

COLL

Piper Sandler analyst David Amsellem has reiterated a Neutral rating for Collegium Pharmaceutical (NASDAQ:COLL) and maintained a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:58 pm

VOYA

RBC Capital analyst Kenneth Lee maintains an Outperform rating on Voya Financial and raises the price target from $83 to $90.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:56 pm

STRO

Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Sutro Biopharma (NASDAQ:STRO) and maintained a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:56 pm

GOOG

Scotiabank analyst Nat Schindler initiated coverage on Alphabet Inc. (NASDAQ:GOOG) with a Sector Outperform rating and a price target of $212, citing Google's strong position in AI and resilience to macroeconomic factors. Despite antitrust actions, the outlook remains positive.

Portfolio Pulse from Lekha Gupta

October 11, 2024 | 5:55 pm

CE

RBC Capital analyst Arun Viswanathan maintains an Outperform rating on Celanese (NYSE:CE) but lowers the price target from $167 to $163.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:54 pm

EMN

RBC Capital analyst Arun Viswanathan maintains a Sector Perform rating on Eastman Chemical (NYSE:EMN) and raises the price target from $100 to $107.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:53 pm

HUN

RBC Capital analyst Arun Viswanathan maintains a Sector Perform rating on Huntsman (NYSE:HUN) and raises the price target from $21 to $24.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:51 pm

CLRB

Oppenheimer analyst Jeff Jones has reiterated an Outperform rating for Cellectar Biosciences (NASDAQ:CLRB) and maintained a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:50 pm

LYB

RBC Capital analyst Arun Viswanathan maintains an Outperform rating on LyondellBasell Industries (NYSE:LYB) but lowers the price target from $112 to $110.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:50 pm

CATX

Oppenheimer analyst Jeff Jones has reiterated an Outperform rating for Perspective Therapeutics (AMEX:CATX) and maintained a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:48 pm